Skip to content

Raw materials at other companies

Organon logo
OrganonOGN
$13M-50.0%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$5.65M
ALN
Alnylam PharmaceuticalsALNY
$11.69M-50.0%
Amgen logo
AmgenAMGN
Incyte logo
IncyteINCY
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterialsNetOfReserves.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s raw materials?
Arcutis Biotherapeutics, Inc. (ARQT) reported raw materials of $16.38M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s raw materials changed year-over-year?
Arcutis Biotherapeutics, Inc.'s raw materials increased by 116.7% year-over-year, from $7.56M to $16.38M.
What does raw materials mean?
Unprocessed materials and components purchased for use in manufacturing, valued at cost.